Rapid and secure AI imaging based diagnosis, stratification, follow-up, and preparedness for coronavirus pandemics


Start Date
End Date
IMI2 - Call 21
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
11 381 970
EFPIA in kind
160 672
Total Cost
11 542 642


Diagnosing COVID-19 and, crucially, predicting how the disease will progress in different patients, remains a challenge. The DRAGON project aims to use artificial intelligence (AI) and machine learning to develop a decision support system capable of delivering a more precise coronavirus diagnosis and more accurate predictions of patient outcomes.

The project will draw on new and existing data and sample collection efforts, including CT (computed tomography) scans to carry out detailed profiling of patients. They will then use AI technology to transform this information into a precision medicine approach that will help clinicians and patients with decision making around treatments.

Underpinning all of this will be a federated machine learning system that will allow the use of data from a range of international sources while complying with the EU’s General Data Protection Regulation (GDPR).

A patient and public advisory group will provide advice and input throughout the project.

Achievements & News

Participants Show participants on map

EFPIA companies
  • Owlstone Medical Limited, Cambridge, United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Centre Hospitalier Universitaire De Liege, Liege, Belgium
  • Department of Health, Leeds, United Kingdom
  • Imperial College Of Science Technology And Medicine, London, United Kingdom
  • The University Of Liverpool, Liverpool, United Kingdom
  • Universita Degli Studi Di Firenze, Florence, Italy
  • Universita Degli Studi Di Parma, Parma, Italy
  • Universiteit Maastricht, Maastricht, Netherlands
  • University Of Southampton, Southampton, United Kingdom
  • University of Cambridge, Cambridge, United Kingdom
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Biosci Consulting Bvba, Maasmechelen, Belgium
  • Cdisc Europe Foundation Fondation, Brussels, Belgium
  • European Respiratory Society, Lausanne, Switzerland
  • Oncoradiomics, Liege, Belgium
  • The Medical Cloud Company, Liege, Belgium
  • Thirona BV, Nijmegen, Netherlands
  • Topmd Precision Medicine LTD, Southampton, United Kingdom
Patient organisations
  • European Lung Foundation, Sheffield, United Kingdom
Project coordinator
Philippe Lambin
Universiteit Maastricht